Gravar-mail: ATIM-17. EARLY RESULTS OF A MULTICENTER PHASE I AND OPEN-LABEL, RANDOMIZED PHASE II STUDY TESTING THE TOXICITIES AND EFFICACY OF MK-3475 (PEMBROLIZUMAB) IN COMBINATION WITH MRI-GUIDED LASER INTERSTITIAL THERMAL THERAPY (LITT) IN RECURRENT MALIGNANT GLIOMAS